Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Cardiology

• Publication date

  2006-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.AMJCARD.2006.04.014PMID 16950182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2006cited by this paper
• Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

  2003cited by this paper
• Lifetime risk for diabetes mellitus in the United States.

  2003cited by this paper
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

  2002cited by this paper
• Disparities in cholesterol screening: falling short of a national health objective.

  2001cited by this paper
• Cardiovascular Disease Risk Factors Among Older Black, Mexican‐American, and White Women and Men: An Analysis of NHANES III, 1988–1994

  2001cited by this paper
• The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.

  2000cited by this paper
• Ethnic variation in cardiovascular disease risk factors among children and young adults: findings from the Third National Health and Nutrition Examination Survey, 1988-1994.

  1999cited by this paper
• Cardiovascular risk factors in Mexican American adults: a transcultural analysis of NHANES III, 1988-1994.

  1999cited by this paper
• Analytical Evaluation of Particle-Enhanced Immunonephelometric Assays for C-Reactive Protein, Serum Amyloid a and Mannose-Binding Protein in Human Serum

  1998cited by this paper
• International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. II. Evaluation and selection of candidate reference materials.

  1992cited by this paper
• International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B.

  1991cited by this paper
• Serum lipids and lipoproteins of Hispanics, 1982-84.

  1990cited by this paper
• Anthropometric data and prevalence of overweight for Hispanics: 1982-84.

  1989cited by this paper
• The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.

  1989cited by this paper
• Anthropometric data and prevalence of overweight for Hispanics: 1982-84.

  1989cited by this paper
• A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol.

  1978cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• Simultaneous Statistical Inference

  1967cited by this paper

• Effects of rosuvastatin treatment and other statins on burn wound healing

  2026cites this paper
• A Meta-Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases

  2025cites this paper
• Effectiveness of HMG-CoA reductase inhibitors on inflammation and metabolic markers in the US-Mexico border Hispanic population

  2024cites this paper
• Cardiovascular Disease Risk Factors in the Hispanic/Latino Population

  2021cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

  2019cites this paper
• Bayesian Meta-Analysis: The Effect of Statins on the Treatment of Hypercholesterolemia

  2018cites this paper
• Opportunities for improving cardiovascular health outcomes in adults younger than 65 years with guideline‐recommended statin therapy

  2017cites this paper
• A comparative study of atorvastatin and rosuvastatin in dyslipidemia

  2017cites this paper
• Lipid-lowering efficacy of rosuvastatin.

  2017cites this paper
• From Sea to Shining Sea and the Great Plains to Patagonia: A Review on Current Knowledge of Diabetes Mellitus in Hispanics/Latinos in the US and Latin America

  2017cites this paper
• National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

  2015cites this paper
• Lipid-lowering efficacy of atorvastatin.

  2015cites this paper
• Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases

  2014cites this paper
• Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study.

  2014cites this paper
• Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials

  2013cites this paper
• Combined Analysis of Pharmacokinetic and Efficacy Data of Preclinical Studies with Statins Markedly Improves Translation of Drug Efficacy to Human Trials

  2013cites this paper
• A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

  2012cites this paper
• Lipid lowering efficacy of atorvastatin.

  2012cites this paper
• [Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].

  2012cites this paper
• Therapeutic Class Overview HMG CoA Reductase Inhibitors

  2012cites this paper
• Improving treatment in Hispanic/Latino patients.

  2011cites this paper
• Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

  2011cites this paper
• Drug safety evaluation of rosuvastatin

  2011cites this paper
• Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of randomised controlled trials

  2010cites this paper
• Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

  2010cites this paper
• Rosuvastatin-Associated Adverse Effects and Drug-Drug Interactions in the Clinical Setting of Dyslipidemia

  2010cites this paper
• Statin Therapy in South Asians—Facts and Future

  2010cites this paper
• Relationship of ethnic origin, gender, and age to blood creatine kinase levels.

  2009cites this paper
• Dyslipidemia in Racial/Ethnic Groups

  2009cites this paper
• Hyperlipidemia in racial/ethnic minorities: differences in lipid profiles and the impact of statin therapy

  2009cites this paper
• CHAPTER 42 – Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups

  2009cites this paper
• Quantitative and qualitative effects of rosuvastatin on LDL‐cholesterol: what is the clinical significance?

  2009cites this paper
• An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability.

  2008cites this paper
• Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia.

  2008cites this paper
• An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability

  2008cites this paper
• Rosuvastatin

  2008cites this paper
• Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

  2008cites this paper
• Comparative Drug Evaluation of Atorvastatin versus Rosuvastatin in Pharmacotherapy of Korean Patients with Dyslipidemia

  2008cites this paper
• Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.

  2008cites this paper
• Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

  2007cites this paper
• Combating racial and ethnic disparities in cardiovascular disease: What is being done?

  2007cites this paper
• Ethnic, gender, and age-related differences in the treatment of dyslipidemia.

  2006cites this paper